Cargando…

Current Status of the Sm14/GLA-SE Schistosomiasis Vaccine: Overcoming Barriers and Paradigms towards the First Anti-Parasitic Human(itarian) Vaccine

Schistosomiasis, a disease historically associated with poverty, lack of sanitation and social inequality, is a chronic, debilitating parasitic infection, affecting hundreds of millions of people in endemic countries. Although chemotherapy is capable of reducing morbidity in humans, rapid re-infecti...

Descripción completa

Detalles Bibliográficos
Autores principales: Tendler, Miriam, Almeida, Marília S., Vilar, Monica M., Pinto, Patrícia M., Limaverde-Sousa, Gabriel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6306874/
https://www.ncbi.nlm.nih.gov/pubmed/30469320
http://dx.doi.org/10.3390/tropicalmed3040121
_version_ 1783382877351706624
author Tendler, Miriam
Almeida, Marília S.
Vilar, Monica M.
Pinto, Patrícia M.
Limaverde-Sousa, Gabriel
author_facet Tendler, Miriam
Almeida, Marília S.
Vilar, Monica M.
Pinto, Patrícia M.
Limaverde-Sousa, Gabriel
author_sort Tendler, Miriam
collection PubMed
description Schistosomiasis, a disease historically associated with poverty, lack of sanitation and social inequality, is a chronic, debilitating parasitic infection, affecting hundreds of millions of people in endemic countries. Although chemotherapy is capable of reducing morbidity in humans, rapid re-infection demonstrates that the impact of drug treatment on transmission control or disease elimination is marginal. In addition, despite more than two decades of well-executed control activities based on large-scale chemotherapy, the disease is expanding in many areas including Brazil. The development of the Sm14/GLA-SE schistosomiasis vaccine is an emblematic, open knowledge innovation that has successfully completed phase I and phase IIa clinical trials, with Phase II/III trials underway in the African continent, to be followed by further trials in Brazil. The discovery and experimental phases of the development of this vaccine gathered a robust collection of data that strongly supports the ongoing clinical phase. This paper reviews the development of the Sm14 vaccine, formulated with glucopyranosyl lipid A (GLA-SE), from the initial experimental developments to clinical trials including the current status of phase II studies.
format Online
Article
Text
id pubmed-6306874
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-63068742019-01-02 Current Status of the Sm14/GLA-SE Schistosomiasis Vaccine: Overcoming Barriers and Paradigms towards the First Anti-Parasitic Human(itarian) Vaccine Tendler, Miriam Almeida, Marília S. Vilar, Monica M. Pinto, Patrícia M. Limaverde-Sousa, Gabriel Trop Med Infect Dis Review Schistosomiasis, a disease historically associated with poverty, lack of sanitation and social inequality, is a chronic, debilitating parasitic infection, affecting hundreds of millions of people in endemic countries. Although chemotherapy is capable of reducing morbidity in humans, rapid re-infection demonstrates that the impact of drug treatment on transmission control or disease elimination is marginal. In addition, despite more than two decades of well-executed control activities based on large-scale chemotherapy, the disease is expanding in many areas including Brazil. The development of the Sm14/GLA-SE schistosomiasis vaccine is an emblematic, open knowledge innovation that has successfully completed phase I and phase IIa clinical trials, with Phase II/III trials underway in the African continent, to be followed by further trials in Brazil. The discovery and experimental phases of the development of this vaccine gathered a robust collection of data that strongly supports the ongoing clinical phase. This paper reviews the development of the Sm14 vaccine, formulated with glucopyranosyl lipid A (GLA-SE), from the initial experimental developments to clinical trials including the current status of phase II studies. MDPI 2018-11-21 /pmc/articles/PMC6306874/ /pubmed/30469320 http://dx.doi.org/10.3390/tropicalmed3040121 Text en © 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Tendler, Miriam
Almeida, Marília S.
Vilar, Monica M.
Pinto, Patrícia M.
Limaverde-Sousa, Gabriel
Current Status of the Sm14/GLA-SE Schistosomiasis Vaccine: Overcoming Barriers and Paradigms towards the First Anti-Parasitic Human(itarian) Vaccine
title Current Status of the Sm14/GLA-SE Schistosomiasis Vaccine: Overcoming Barriers and Paradigms towards the First Anti-Parasitic Human(itarian) Vaccine
title_full Current Status of the Sm14/GLA-SE Schistosomiasis Vaccine: Overcoming Barriers and Paradigms towards the First Anti-Parasitic Human(itarian) Vaccine
title_fullStr Current Status of the Sm14/GLA-SE Schistosomiasis Vaccine: Overcoming Barriers and Paradigms towards the First Anti-Parasitic Human(itarian) Vaccine
title_full_unstemmed Current Status of the Sm14/GLA-SE Schistosomiasis Vaccine: Overcoming Barriers and Paradigms towards the First Anti-Parasitic Human(itarian) Vaccine
title_short Current Status of the Sm14/GLA-SE Schistosomiasis Vaccine: Overcoming Barriers and Paradigms towards the First Anti-Parasitic Human(itarian) Vaccine
title_sort current status of the sm14/gla-se schistosomiasis vaccine: overcoming barriers and paradigms towards the first anti-parasitic human(itarian) vaccine
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6306874/
https://www.ncbi.nlm.nih.gov/pubmed/30469320
http://dx.doi.org/10.3390/tropicalmed3040121
work_keys_str_mv AT tendlermiriam currentstatusofthesm14glaseschistosomiasisvaccineovercomingbarriersandparadigmstowardsthefirstantiparasitichumanitarianvaccine
AT almeidamarilias currentstatusofthesm14glaseschistosomiasisvaccineovercomingbarriersandparadigmstowardsthefirstantiparasitichumanitarianvaccine
AT vilarmonicam currentstatusofthesm14glaseschistosomiasisvaccineovercomingbarriersandparadigmstowardsthefirstantiparasitichumanitarianvaccine
AT pintopatriciam currentstatusofthesm14glaseschistosomiasisvaccineovercomingbarriersandparadigmstowardsthefirstantiparasitichumanitarianvaccine
AT limaverdesousagabriel currentstatusofthesm14glaseschistosomiasisvaccineovercomingbarriersandparadigmstowardsthefirstantiparasitichumanitarianvaccine